Success Metrics

Active Trials
12(100%)

Phase Distribution

Ph phase_1
1
8%
Ph phase_2
5
42%
Ph phase_3
6
50%

Phase Distribution

1

Early Stage

5

Mid Stage

6

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
5(41.7%)
Phase 3Large-scale testing
6(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

12

trials recruiting

Total Trials

12

all time

Status Distribution
Active(12)

Detailed Status

Recruiting9
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
12
Active
12
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (8.3%)
Phase 25 (41.7%)
Phase 36 (50.0%)

Trials by Status

active_not_recruiting325%
recruiting975%

Recent Activity

Clinical Trials (12)

Showing 12 of 12 trials
NCT06863961Phase 2

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

Active Not Recruiting
NCT07298421Phase 3

A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

Recruiting
NCT07223697Phase 2

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Recruiting
NCT06588855Phase 3

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
NCT06819891Phase 3

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Recruiting
NCT07137598Phase 2

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

Recruiting
NCT07620392Phase 2

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

Recruiting
NCT07665723Phase 1

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

Recruiting
NCT06819878Phase 3

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Recruiting
NCT07158242Phase 3

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Recruiting
NCT05910528Phase 2

Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

Active Not Recruiting
NCT06589986Phase 3

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Active Not Recruiting

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12